United Therapeutics Corp at Wedbush PacGrow Healthcare Conference Transcript
Hello. Thank you for attending the Wedbush Healthcare Conference. I'm Liana Moussatos, one of the senior analysts. It's our great pleasure to have a fireside chat, Q&A with the CEO and CFO of United Therapeutics and get an update; the CEO, Dr. Martine Rothblatt and the CFO, James Edgemond.
Dr. Rothblatt has led the company to develop breakthrough treatments in delivery systems for PAH and delivered early profitability, top and bottom line growth and significant free cash flow, which makes United Therapeutics unusual and -- especially in my coverage.
Questions & Answers
Dr. Rothblatt, on the Q2 call, you projected tripling in revenues, but near term analysts' projections imply that top and bottom line growth may be bumpy for the next couple of years as the company transitions dependence on generation 1 delivery for Remodulin and Tyvaso to generation 2
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |